Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT02728388
PHASE2

Photodynamic Therapy for Benign Dermal Neurofibromas- Phase II

Sponsor: Donald Basel

View on ClinicalTrials.gov

Summary

The investigators wish to determine the time to disease progression for benign neurofibromas treated with Levulan Kerastick topical photosensitizer and red light photodynamic therapy (PDT) in patients with neurofibromatosis type 1 (NF1). The investigators also wish to measure tumor size for control and treatment tumors in order to gain insights into tumor growth rates.

Official title: Topical Photodynamic Therapy (PDT) With Levulan® Kerastick® for Benign Dermal Neurofibromas Phase II

Key Details

Gender

All

Age Range

14 Years - 30 Years

Study Type

INTERVENTIONAL

Enrollment

30

Start Date

2016-08

Completion Date

2025-12

Last Updated

2025-05-08

Healthy Volunteers

No

Interventions

DRUG

aminolevulinic acid

Drug: Levulan Kerastick Drug: Topical placebo Device: Omnilux Revive Procedure: Photodynamic therapy Other: Tumor growth rate measurements

Locations (1)

Donald G Basel

Milwaukee, Wisconsin, United States